共 86 条
[1]
Hodgson SH(2021)What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 Lancet Infect Dis 21 e26-e35
[2]
Mansatta K(2020)Approaches and challenges in SARS-CoV-2 vaccine development Cell Host Microbe 28 364-370
[3]
Mallett G(2021)Viral targets for vaccines against COVID-19 Nat Rev Immunol 21 73-82
[4]
Harris V(2021)Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial JAMA 326 35-45
[5]
Emary KRW(2021)Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile N Engl J Med. 385 875-84
[6]
Pollard AJ(2022)Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study Lancet Infect Dis. 22 1435-43
[7]
Dagotto G(2022)BNT162b2 mRNA vaccine effectiveness given confirmed exposure: analysis of household members of coronavirus disease 2019 patients Clin Infect Dis. 75 e734-40
[8]
Yu JY(2022)Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study Am J Epidemiol. 191 1224-34
[9]
Barouch DH(2022)Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE J Travel Med. 398 856-69
[10]
Dai LP(2021)Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial Lancet. 22 959-66